CYCC

Cyclacel Pharmaceuticals, Inc.

1.77 USD
+0.02 (+1.14%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cyclacel Pharmaceuticals, Inc. stock is down -13.66% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 15.79% of the previous 18 June’s closed higher than May.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc. develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) and CYC140. Sapacitabine, a nucleoside analog that is orally available prodrug of CNDAC, is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome.